REACH2: Ruxolitinib outperformed control treatment for refractory acute GVHDApril 22, 2020Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersTransplantation
Want to keep cancer patients and providers safe during the pandemic? Here’s howApril 20, 2020Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersPediatrics
Oncologists need to advocate for scarce COVID-19 resources: ASCOApril 15, 2020Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersPediatrics
ASCO announces its own COVID-19 and cancer registryApril 13, 2020Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersPediatrics
Cancer prevalence among COVID-19 patients may be higher than previously reportedApril 13, 2020Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersPediatrics
Home-based chemo skyrockets at one U.S. centerApril 10, 2020Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell Disorders
Managing pediatric heme/onc departments during the pandemicApril 9, 2020PediatricsLymphoma & Plasma Cell DisordersLeukemia, Myelodysplasia, Transplantation
Conducting cancer trials amid the COVID-19 pandemicApril 8, 2020PediatricsLymphoma & Plasma Cell DisordersLeukemia, Myelodysplasia, Transplantation
First advance in MDS for decade: Luspatercept for anemiaApril 6, 2020Leukemia, Myelodysplasia, TransplantationAnemia
‘Brutal’ plan to restrict palliative radiation during pandemicApril 6, 2020Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersPediatrics
Maintaining cancer care in the face of COVID-19April 1, 2020Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersMultiple MyelomaPediatrics
